Literature DB >> 20466616

Lymphoma of the testis as primary location: tumour review.

Georgios Koukourakis1, Vassilios Kouloulias.   

Abstract

Non-Hodgkin's lymphoma as a primary testicular neoplasm accounts approximately 9% of all testicular malignant tumours and about 1-2% of all non-Hodgkin's lymphoma. This neoplasm is the most common malignant tumour of the testis in the elderly. The most common histotype in primary forms is the diffuse large B-cell lymphoma, whereas more aggressive histologies such as Burkitt's lymphoma are principal founded in cases of secondary involvement of the testis. Regarding clinical presentation, the most common sign is a unilateral painless scrotal swelling, sometimes with sharp scrotal pain or hydrocele. In patients with advanced stage, the systematic B symptoms are present in 25-41% of all cases. In 35% of patients, bilateral testicular involvement is detected. In more advanced stages with para-aortic lymph-node involvement, ascites and abdominal pain is evident. Despite the fact that responses to doxorubicin- containing chemotherapy, especially in early stages, show good results, relapses are often seen, and the prognosis of this tumour is very poor. Testicular lymphoma often disseminates to other extranodal organs, such as contralateral testis, central nervous system (CNS), lung, pleura, Waldeyer's ring and soft tissue. For patients with limited disease, the recommended first-line treatment is orchiectomy followed by rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) combination chemotherapy, with central nervous system (CNS) prophylaxis and prophylactic irradiation of the contralateral testis. In more advanced or relapsed disease, management should follow the worldwide recommendations for nodal diffuse large B-cell lymphoma (DLBCL). Here we present a review of this tumour.

Entities:  

Mesh:

Year:  2010        PMID: 20466616     DOI: 10.1007/s12094-010-0513-9

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  41 in total

1.  Anthracycline-based chemotherapy of primary non-Hodgkin's lymphoma of the testis: the hellenic cooperative oncology group experience.

Authors:  D Pectasides; T Economopoulos; G Kouvatseas; A Antoniou; Z Zoumbos; G Aravantinos; C Tsatalas; A Halikia; C Nikolaides; C Kiamouris; E Pappa; N Pavlidis; D Skarlos; G Fountzilas; M A Dimopoulos
Journal:  Oncology       Date:  2000-05       Impact factor: 2.935

2.  Intracranial malignant lymphoma developing 20 years after total removal of testicular malignant lymphoma--case report.

Authors:  Y Ikeda; S Nakazawa; M Kudo
Journal:  Neurol Med Chir (Tokyo)       Date:  1986-01       Impact factor: 1.742

3.  Malignant lymphoma of the testis in Indians.

Authors:  M B Sampat; M V Sirsat; M R Kamat
Journal:  Br J Urol       Date:  1974-10

Review 4.  Malignant lymphoma of the testis.

Authors:  D C Doll; R B Weiss
Journal:  Am J Med       Date:  1986-09       Impact factor: 4.965

5.  Brief chemotherapy and involved-region irradiation for limited-stage diffuse large-cell lymphoma: an 18-year experience from the British Columbia Cancer Agency.

Authors:  Tamara N Shenkier; Nicholas Voss; Randall Fairey; Randy D Gascoyne; Paul Hoskins; Richard Klasa; Paul Klimo; Susan E O'Reilly; Simon Sutcliffe; Joseph M Connors
Journal:  J Clin Oncol       Date:  2002-01-01       Impact factor: 44.544

6.  Non-Hodgkin's lymphoma affecting the testis: is it curable with doxorubicin-based therapy?

Authors:  C Visco; L J Medeiros; O M Mesina; M A Rodriguez; F B Hagemeister; P McLaughlin; J E Romaguera; F Cabanillas; A H Sarris
Journal:  Clin Lymphoma       Date:  2001-06

7.  Malignant lymphoma of the testis.

Authors:  S Ciatto; L Cionini
Journal:  Acta Radiol Oncol Radiat Phys Biol       Date:  1979

8.  High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology.

Authors:  Upendra Hegde; Armando Filie; Richard F Little; John E Janik; Nicole Grant; Seth M Steinberg; Kieron Dunleavy; Elaine S Jaffe; Andrea Abati; Maryalice Stetler-Stevenson; Wyndham H Wilson
Journal:  Blood       Date:  2004-09-09       Impact factor: 22.113

9.  Malignant lymphoma of the testis.

Authors:  M M Fickers; J Koudstaal; F P van de Weijer; T A Verschueren
Journal:  Neth J Med       Date:  1991-08       Impact factor: 1.422

10.  Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group.

Authors:  E Zucca; A Conconi; T I Mughal; A H Sarris; J F Seymour; U Vitolo; R Klasa; M Ozsahin; G M Mead; M A Gianni; S Cortelazzo; A J M Ferreri; A Ambrosetti; M Martelli; C Thiéblemont; H Gomez Moreno; G Pinotti; G Martinelli; R Mozzana; S Grisanti; M Provencio; M Balzarotti; F Laveder; G Oltean; V Callea; P Roy; F Cavalli; M K Gospodarowicz
Journal:  J Clin Oncol       Date:  2003-01-01       Impact factor: 44.544

View more
  4 in total

1.  Percutaneous testicular biopsy for indeterminate testicular lesions.

Authors:  N Shaida; L H Berman
Journal:  Br J Radiol       Date:  2012-06-06       Impact factor: 3.039

2.  Twenty-year Experience with Genitourinary Lymphoma at a Community Hospital.

Authors:  Yazhini Vallatharasu; Adithya Chennamadhavuni; Marvin J Van Every
Journal:  Clin Med Res       Date:  2021-03-31

3.  [The clinical characteristics and outcomes of 16 Burkitt' s lymphoma with testicular involvement].

Authors:  S Huang; L Jin; J Yang; Y L Duan; M Zhang; C J Zhou; Y H Zhang
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2016-09-14

4.  The Mutation of BTG2 Gene Predicts a Poor Outcome in Primary Testicular Diffuse Large B-Cell Lymphoma.

Authors:  Dan Guo; Lemin Hong; Hao Ji; Yuwen Jiang; Ling Lu; Xinfeng Wang; Hongming Huang
Journal:  J Inflamm Res       Date:  2022-03-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.